Humanigen (HGENQ) 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Exhibit 16.1

 

December 23, 2015

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read the statements made by KaloBios Pharmaceuticals, Inc. under Item 4.01 of its Form 8-K dated December 21, 2015. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of KaloBios Pharmaceuticals, Inc. contained therein.

Very truly yours,